NEW YORK – Though testing laboratories and test manufacturers have been making improvements to mitigate the effects of biotin interference in immunoassay testing, it remains a headache that both continue to have to grapple with.
"We're not completely out of the woods," Brooke Katzman, a codirector of the hospital clinical laboratory and point-of-care testing at the Mayo Clinic, said in an interview.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
